Novo Nordisk sues pharmacies over impure Wegovy, Ozempic dupes
A 0.25 mg injection pen of Novo Nordisk's weight-loss drug Wegovy is shown in this photo illustration in Oslo, Norway, August 31, 2023.Victoria Klesty | ReutersNovo Nordisk on Thursday said it sued two compounding pharmacies in Florida for allegedly selling impure and "potentially unsafe" drugs claiming to contain semaglutide, the active ingredient in the drugmaker's blockbuster weight loss treatment Wegovy and diabetes medication Ozempic. The actions come as Novo Nordisk grapples with shortages of Wegovy and Ozempic in…